Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Immunization against Multidrug-resistant Pathogens: Activating T Cell Immunity (IMPACT-CETR)

Award Number: U19AI189176
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/19/2025
PERIOD OF PERFORMANCE END DATE: 06/30/2030

Group Awards By:

View Award Description

Immunization against Multidrug-resistant Pathogens: Activating T Cell Immunity (IMPACT-CETR) - Overall Project Abstract The overall focus of the “Immunization against Multidrug-resistant Pathogens: Activating T Cell Immunity” Center of Excellence for Translational Research (IMPACT-CETR) is to advance promising multicomponent vaccines for Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae. These are among the most important bacterial pathogens that cause severe clinical disease and death and yet are becoming increasingly resistant to the most effective antibiotics. The overarching goal of this IMPACT-CETR is to harness the collaborative team’s complementary expertise in immunology, bacteriology, bioinformatics, primatology, vaccine development, and antigen-adjuvant formulations to achieve three deliverables: 1) novel multicomponent vaccines optimized for bacterial proteins and/or polysaccharides that elicit broad and potent serotype- independent protection against S. aureus, P. aeruginosa, and K. pneumoniae infections, including with resistant and MDR clinical isolates; 2) defined key mechanisms of host protection and biomarkers of vaccine efficacy; and 3) nonhuman primate (NHP) models to characterize immunogenicity and surrogate markers of protection. The proposed vaccine components are well-characterized, some are chemically defined, and all are designed for feasible scale-up and manufacture. The three research projects in this CETR are bonded by the theme that tissue-resident memory T cell responses, particularly tissue-resident Th17 cells, are critical for protective vaccines against these pathogens. The translational research projects will develop countermeasures to prevent/reduce disease caused by key resistant and MDR bacterial pathogens. Project 1 addresses a multicomponent S. aureus vaccine formulated with conserved protein antigens using the new and innovative Multiple Antigen Presenting System (MAPS) platform wherein fusion proteins of the avidin derivative rhizavidin with conserved S. aureus protein antigens are complexed to a biotinylated polysaccharide to generate protective B- and T-cells. Project 2 addresses a multicomponent P. aeruginosa MAPS vaccine based on the serotype- independent P. aeruginosa biofilm polysaccharide Psl and its critical lipid epitope, combined with conserved protein antigens including the Th17-eliciting antigen PopB. Project 3 addresses a quadrivalent K. pneumoniae vaccine based on conserved proteins that elicit protective Th17 cells and antibodies. Vaccine candidates will be tested in wild-type and transgenic and/or knock-out mice and in non-human primates. These projects will be supported by an administrative core and three scientific cores that focus on bioinformatics, transgenic mouse models for mechanistic studies, and NHP studies. The expected milestone for each project is the development of a preclinical data package that would pave the way for subsequent IND applications and clinical trials.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $5,179,700 )
2026	2026	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Allergy and Infectious Diseases Research	001	2	7/1/2026	NON-COMPETING CONTINUATION	$5,179,700
2026	2025	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	1	11/28/2025	NEW	$0
														Subtotal = $5,179,700

Issue Date FY: 2025 ( Subtotal = $4,776,780 )
2025	2025	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	1	8/19/2025	NEW	$4,776,780
														Subtotal = $4,776,780

Grand Total All Awards = $9,956,480

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Immunization against Multidrug-resistant Pathogens: Activating T Cell Immunity (IMPACT-CETR)

Award Number: U19AI189176

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/19/2025

PERIOD OF PERFORMANCE END DATE: 06/30/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer